ConductScience.org, home

Paper628005

Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.

Zee-Cheng RK and 1 other. J Med Chem, 1978. Cited by 249 papers, by iCite.

Cite this record

ConductScience Library. Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones. Papers, record 628005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/628005

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
PubMed
Journal
J Med Chem
PubMed
Year
1978
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
249
iCite
Relative citation ratio, by iCite
8.61
iCite
Revised in PubMed
2019-07-09
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zee-Cheng RKR K
2Cheng CCC C

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AnthraquinonesMajor topic
Leukemia, ExperimentalMajor topic
Animals
Antineoplastic Agents
Melanoma
Mice
Neoplasms, Experimental
Structure-Activity Relationship

Source PubMed

Download CSV of topics

Cited by35

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 249 citations.

PMIDTitleJournalYearIn PapersSource
37821106In vitro reconstitution of SARS-CoV-2 Nsp1-induced mRNA cleavage reveals the key roles of the N-terminal domain of Nsp1 and the RRM domain of eIF3g.Genes Dev2023https://conductscience.org/library/papers/37821106PubMed
33562300Drug Combination in Cancer Treatment-From Cocktails to Conjugated Combinations.Cancers (Basel)2021https://conductscience.org/library/papers/33562300PubMed
32975138DNA topoisomerases as molecular targets for anticancer drugs.J Enzyme Inhib Med Chem2020https://conductscience.org/library/papers/32975138PubMed
30005668Binding mechanism of anti-cancer chemotherapeutic drug mitoxantrone to DNA characterized by magnetic tweezers.J Nanobiotechnology2018https://conductscience.org/library/papers/30005668PubMed
28820965Systematic Identification of MCU Modulators by Orthogonal Interspecies Chemical Screening.Mol Cell2017https://conductscience.org/library/papers/28820965PubMed
28523107Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.ACS Med Chem Lett2017https://conductscience.org/library/papers/28523107PubMed
21528870Asymmetric enzymatic glycosylation of mitoxantrone.Org Lett2011https://conductscience.org/library/papers/21528870PubMed
20135310Chemotherapeutic potential of 9-phenyl acridine: biophysical studies on its binding to DNA.Eur Biophys J2010https://conductscience.org/library/papers/20135310PubMed
17483512Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent.Nucleic Acids Res2007https://conductscience.org/library/papers/17483512PubMed
17074670Anticancer drug discovery and pharmaceutical chemistry: a history.Clin Transl Oncol2006https://conductscience.org/library/papers/17074670PubMed
8918789Site-specific and photo-induced alkylation of DNA by a dimethylanthraquinone-oligodeoxynucleotide conjugate.Nucleic Acids Res1996https://conductscience.org/library/papers/8918789PubMed
8262731Mitoxantrone (dihydroxyanthracenedione) in acute leukemia. An evaluation of two treatment schedules by the Southwest Oncology Group.Invest New Drugs1993https://conductscience.org/library/papers/8262731PubMed
8190623DNA sequence specificity of mitoxantrone.Nucleic Acids Res1994https://conductscience.org/library/papers/8190623PubMed
7460190Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/7460190PubMed
7196864The immunoinhibitory and immunostimulatory effects of hydroxyanthra- and hydroxynaphthoquinone derivatives.Folia Microbiol (Praha)1981https://conductscience.org/library/papers/7196864PubMed
7105379Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7105379PubMed
7094196Pharmacology of mitoxantrone in cancer patients.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7094196PubMed
6690066Mitoxantrone: an active new agent in the treatment of advanced breast cancer.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6690066PubMed
6687221Correlation of the structure of amino-substituted anthraquinones to cytotoxicity in cultured Chinese hamster cells.Invest New Drugs1983https://conductscience.org/library/papers/6687221PubMed
6678863Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system.Invest New Drugs1983https://conductscience.org/library/papers/6678863PubMed

See all 35 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/628005

GET https://conductscience.org/api/papers/v1/628005/cited_by?page=2